NCT02146924View on ClinicalTrials.gov

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

October 16, 2014

Primary Completion Date

September 24, 2025

Study Completion Date

September 24, 2025

Conditions
B Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes

Given IV

BIOLOGICAL

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER